International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com),
a California-based, early-stage stem cell therapeutics company,
announced today that Rouslan Semechkin has joined its Board of Directors.
International Stem Cell Corporation's focus is
on the development of stem cell based treatment of diabetes, liver
disease and diseases of the retina and providing specialized cells and
media to others for cell based research. It maintains corporate and
research facilities in Oceanside, California; production and product
development in Walkersville, Maryland; and international research
facilities in Moscow, Russia.
Mr. Semechkin brings to International Stem Cell Corporation both
scientific expertise and international relationships. He is an honors
graduate of the Moscow State University and is a specialist in the
analysis of biological processes and mathematical modeling in biology.
He is a Member of the American Mathematical Society and President of
X-Master, Inc., a New Hampshire based company with investments in real
estate and other assets.
About International Stem Cell Corporation (ISCO.OB):
International Stem Cell Corporation (ISCO) is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of
pluripotent human stem cell lines from unfertilized human eggs. ISCO
scientists also have created the first Parthenogenetic homozygous
stem cell line (phSC-Hhom-4) that can be a source of therapeutic
cells that will not be immune rejected after transplantation into
millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by
eliminating the need to use or destroy fertilized embryos. ISCO also
produces and markets specialized cells and growth media worldwide for
therapeutic research through its subsidiary Lifeline Cell Technology.
For more information, visit the ISCO website at: www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
Forward-Looking Statements Statements pertaining to future financial and/or operating results,
future growth in research, technology, clinical development and
potential opportunities for the company and its subsidiary, along with
other statements about the future expectations, beliefs, goals, plans,
or prospects expressed by management constitute forward-looking
statements. Any statements that are not historical fact (including, but
not limited to statements that contain words such as "will,""believes,""plans,""anticipates,""expects,""estimates,")
should also be considered to be forward-looking statements.
Forward-looking statements involve risks and uncertainties, including,
without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, and maintenance of intellectual property rights. Actual
results may differ materially from the results anticipated in these
forward-looking statements and as such should be evaluated together with
the many uncertainties that affect the company's business, particularly
those mentioned in the cautionary statements found in the company's
Securities and Exchange Commission filings. The company disclaims any
intent or obligation to update these forward-looking statements. Key Words:Stem Cells, Biotechnology, Parthenogenesis, Liver
Disease; Diabetes; Retinal Disease
International Stem Cell Corporation Kenneth C. Aldrich, CEO,
760-940-6383 kaldrich@intlstemcell.com or William
B. Adams, CFO, 760-940-6383 wadams@intlstemcell.com or Jeffrey
Janus, President, 760-940-6383 jjanus@intlstemcell.com |